Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Health Network, Toronto
With
Novartis Pharmaceuticals
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
One of the three classical Philadelphia negative myeloproliferative neoplasms (polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF)) diagnosed according to WHO or International working group-Myelofibrosis research and treatment (IWG-MRT) criteria
Palpable spleen length greater than 5 cm below the costal margin in MF (including primary MF or post-polycythemia vera MF (PPV-MF) post-polycythemia vera ET (PPV-ET)) or palpable spleen of any size in patients with PV or ET.
Ability to understand and willing to sign a written consent form.
Age 18 years or older at time of consent.
You may not be if
Known history of portal vein thrombosis
Known history of Budd-chairi syndrome
Known history of oesophageal varices
Known history of cirrhosis from any cause
Known history of active bleeding
Clareo Health | Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms
